De­sign Ther­a­peu­tics hints at ‘strate­gic re­align­ment,’ re­places CEO; Karyopharm co-founder leads AT­P's Nereid

→ De­sign Ther­a­peu­tics chair­man Pratik Shah has suc­ceed­ed João Sif­fert as CEO while teas­ing a “strate­gic re­align­ment” that won’t be re­vealed un­til ear­ly 2024, ac­cord­ing to its Q3 re­port. De­sign does elab­o­rate on the sta­tus of its cash run­way, which is pro­ject­ed to keep the lights on “through 2028” as a re­sult of the changes. Shah has chaired the board since 2017 and is con­nect­ed to two Lau­ra Shawver biotechs as the ex-chair­man of Syn­thorx — pur­chased by Sanofi — and the cur­rent chair­man at ARS Phar­ma­ceu­ti­cals, which merged with Shawver-led Sil­ver­back Ther­a­peu­tics last year. Sif­fert took the top spot at De­sign in Oc­to­ber 2020 af­ter re­sign­ing as CEO, head of R&D and CMO at Abeona Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER